SS
FHTX icon

SBI Securities’s Foghorn Therapeutics FHTX Stock Holding History

SBI Securities’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$478 Hold
100
– – ﹤0.01% 2907
2025
Q4 		$540 Hold
100
– – ﹤0.01% 2847
2025
Q3 		$489 Hold
100
– – ﹤0.01% 2973
2025
Q2 		$470 Hold
100
– – ﹤0.01% 2992
2025
Q1 		$365 Buy
100
+99
+9,900% +$451 ﹤0.01% 2995
2024
Q4 		$5 Buy
+1
New +$7 ﹤0.01% 3996

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

SBI Securities's FHTX Position: Q1 2026 in Review

SBI Securities held its Foghorn Therapeutics (FHTX) position steady in Q1 2026 at 100 shares worth $478. The position accounts for ﹤0.01% of the portfolio, ranked #2907.

SBI Securities first reported a position in FHTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $540 in Q4 2025. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • SBI Securities held 100 shares of Foghorn Therapeutics worth $478 as of Q1 2026.
  • SBI Securities left its Foghorn Therapeutics share count unchanged in Q1 2026.
  • Foghorn Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #2907 holding.
  • SBI Securities first reported a position in Foghorn Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • SBI Securities's Foghorn Therapeutics position peaked at $540 in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.